The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies.
Sara A. Hurvitz
Honoraria - Roche/Genentech
Annie Guerin
Employment or Leadership Position - Analysis Group
Research Funding - Genentech
Melissa G. Brammer
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Ellie Guardino
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Zheng-Yi Zhou
Employment or Leadership Position - Analysis Group
Michael S Kaminsky
Employment or Leadership Position - Analysis Group
Eric Q. Wu
Employment or Leadership Position - Analysis Group
Deepa Lalla
Employment or Leadership Position - Genentech
Stock Ownership - Roche